Keywords: good, efficacy, gilead, sci, arv, combo, drugmaker
Good efficacy for Gilead Sci's ARV combo
Article | 30 January 2006
US drugmaker Gilead Sciences says that a once-daily treatment regimen of its anti-HIV drugs Viread (tenofovir disoproxil fumarate), Emtriva (emtricitabine) ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
